StratifiREY
Liver Cancer
6th
most common
cancer globally
3rd
leading cause of
cancer-related death
worldwide in 2020
>1 Million
individuals are estimated
to be affected by
liver cancer by 2025
Y90 Radioembolization
Hepatocellular Carcinoma (HCC) is the most common type of liver cancer.
Y90 Radioembolization (RE), also known as transarterial radioembolization (TARE), is one of the treatment options for unresectable HCC.
Y90 RE involves the injection of glass or resin microspheres containing radioactive yttrium-90 into the liver artery via a catheter
Microspheres are lodged in the small blood vessels near the tumour, where they release radiation to the tumour.
As the radiation is delivered directly to the tumour, its effects are limited mainly to the tumour while the liver remains relatively unaffected.
2
1
Challenge
Clinicians are unable to predict if a patient will respond to Y90 RE treatment and patients have to wait 3 to 6 months before knowing whether Y90 RE had worked
Liver cancer patient
Treatment with Y90 RE
Only 3 out of 10 patients
will respond* to treatment**
*Defined by lack of disease progression at 6 months post-treatment
**Based on preliminary study
.png)
Unnecessary healthcare expenses and valuable time loss
Solution
StratifiREY can predict if a patient will respond to Y90 RE to help clinicians make more informed decisions on whether the patient should proceed with Y90 RE or alternative treatments
Predicted
responders
Liver cancer patient
Use of StratifiREY Y90 RE Companion Diagnostic Test
Treatment with Y90 RE
Predicted
non-responders
7 predicted non-sustained responders referred to alternative treatment such as TACE or immunotherapy
Avoid unnecessary Y90 RE treatment and patients do not have to wait for 3-6 months to see if Y90 RE works
All 3 predicted responders respond to Y90 RE treatment
How StratifiREY works
Recent research has found that Y90 RE recruits activated white blood cells (WBCs) to the liver, where they kill the tumour cells. This radiation-induced immune response is a possible reason why maximum clinical response is only observed 3 to 6 months after treatment with Y90 RE although the radiation dissipates after 2 weeks.
StratifiREY is an immune-profiling companion diagnostic test that uses a panel of WBC biomarkers to determine a patient's response to Y90 RE.
1
Collect patient's blood sample and isolate peripheral blood mononuclear cells (PBMC)
2
PBMC analysed using flow cytometry
3
Analysis of results using a machine learning prediction model to determine patient's response to Y90 RE
Benefits
Ease of mind
Patients do not have to wait for 3 to 6 months before knowing whether they have responded to Y90 RE treatment
Cost Savings
Save on unnecessary Y90 RE treatment cost if patient is predicted to be a non-sustained responder
.png)
More informed decision
Clinicians will have more information to decide which treatment is better suited for the patient
Assay Accuracy
82% sensitivity and 100% specificity.*
* Based on preliminary studies